Does the immune system see tumors as foreign or self?

Annual Review of Immunology

Volumn 21, Issue , 2003, Pages 807-839

  Pardoll, Drew ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Immune escape; Immune surveillance; NKG2D; Tumor tolerance

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FAS LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; STAT3 PROTEIN; TACHYKININ RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; NATURAL KILLER CELL ACTIVATING RECEPTORS;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; DRUG EFFECT; HETEROZYGOSITY LOSS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; LYMPHOCYTE; MELANOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; TUMOR IMMUNITY; TUMOR RESISTANCE; VACCINATION; ANIMAL; BIOLOGICAL MODEL; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOUSE; NEOPLASM;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MICE; MODELS, IMMUNOLOGICAL; MONITORING, IMMUNOLOGIC; NEOPLASMS; RECEPTORS, IMMUNOLOGIC;

EID: 0042470540     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.21.120601.141135     Document Type: Review

References (189)

1. Fearon ER, Vogelstein BA. 1990. Genetic model for colorectal tumorogenesis. Cell 61:759-67
2. Lu X, Lane DP. 1993. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 75:765-78
3. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. 1998. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281:1009-12
4. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, et al. 1997. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386:804-10
5. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, et al. 1993. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027-38
6. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, et al. 1993. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215-25
7. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, et al. 1994. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368:258-61
8. Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, et al. 1994. Mutation of a mutL homolog in hereditary colon cancer. Science 263:1625-29
9. Thomas L. 1959. Discussion of Cellular and Humoral Aspects of the Hypersensitive States, ed. HS Lawrence. New York: Hoeber-Harper
10. Burnet FM. 1970. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13:1-27
11. Gross L. 1943. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 3:326-33
12. Foley EJ. 1953. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 13:835-37
13. Baldwin RW. 1955. Immunity to methylcholanthrene-induced tumors in inbred rats following atrophy and regression of implanted tumors. Br. J. Cancer 9:652-65
14. Prehn RT. 1957. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18:769-78
15. Old LJ, Boyse EA, Clark DA, Carswell EA. 1962. Antigenic properties of chemically-induced tumors. Ann. NY Acad. Sci. 101:80-106
16. Stutman O. 1979. Tumor development after 3-methylcholanthrene in immunologically deficient athymic nude mice. Science 183:534-36
17. Outzen HC, Custer RP, Eaton GJ, Prehn RT. 1975. Spontaneous and induced tumor incidence in germfree "nude" mice. J. Reticuloendothel. Soc. 17:1-9
18. Rygaard J, Povlsen CO. 1976. The nude mouse vs. the hypothesis of immunological surveillance. Transplant. Rev. 28:43-61
19. Moller G. 1976. Experiments and the concept of immunological surveillance. Transplant Rev. 28:1-97
20. Holland JM, Mitchell TJ, Gipson LC, Whitaker MS. 1978. Survival and cause of death in aging germfree athymic nude and normal inbred C3Hf/He mice. J. Natl. Cancer Inst. 61:1357-61
21. Penn I. 1988. Tumors of the immunocompromised patient. Annu. Rev. Med. 39:63-73
22. List AF, Greco FA, Vogler LB. 1987. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. J. Clin. Oncol. 5:1673-89
23. Gaidano G, Dalla FR. 1992. Biologic aspects of human immunodeficiency virus-related lymphoma. Curr. Opin. Oncol. 4:900-6
24. Frizzera G. 1992. Neoplastic Hematopathology, ed. DM Knowles, pp. 459-95. Baltimore: Williams & Wilkins
25. Heslop HE, Ng CYC, Li CF, Smith CA, Loftin SK, et al. 1996. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2:551-55
26. Mesri EA, Cesarman E, Arvanitakis L, Rafii S, Moore MA, et al. 1996. Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells. J. Exp. Med. 183:2385-90
27. Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, et al. 1984. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 3:1151-57
28. Beaudenon S, Kremsdorf D, Obalek S, Jablonska S, Pehau-Arnaudet G, et al. 1987. Plurality of genital human papillomaviruses: characterization of two new types with distinct biological properties. Virology 161:374-84
29. McFarlane GA, Munro A. 1997, Helicobacter pylori and gastric cancer. Br. J. Surg. 84:1190-99
30. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, et al. 1998. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95:7556-61
31. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, et al. 2001. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107-11
32. Street SE, Trapani JA, MacGregor D, Smyth MJ. 2002. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J. Ex. Med.: 129-34
33. Lefrancois L, Fuller B, Huleatt JW, Olson S, Puddington L. 1997. On the front lines: intraepithelial lymphocytes as primary effectors of intestinal immunity. Springer Semin. Immunopathol. 18:463-75
34. Allison JP. 1991. Gamma delta T cells in murine epithelia: origin, repertoire, and function. Adv. Exp. Med. Biol. 292:63-69
35. Nandi D, Allison JP. 1991. Phenotypic analysis and gamma delta-T cell receptor repertoire of murine T cells associated with the vaginal epithelium. J. Immunol. 147:1773-78
36. Asarnow DM, Kuziel WA, Bonyhadi M, Tigelaar RE, Tucker PW, et al. 1988. Limited diversity of gamma delta antigen receptor genes of Thy-1+ dendritic epidermal cells. Cell 55:837-47
37. Asarnow DM, Goodman T, LeFrancois L, Allison JP. 1989. Distinct antigen receptor repertoires of two classes of murine epithelium-associated T cells. Nature 341:60-62
38. Holtmeier W, Pfänder M, Hennemann A, Zollner TM, Kaufmann R, Caspary WF. 2001. The TCR-delta repertoire in normal human skin is restricted and distinct from the TCR-delta repertoire in the peripheral blood. J. Invest. Dermatol. 116:275-80
39. Havran WL, Chien YH, Allison JP. 1991. Recognition of self antigens by skin-derived T cells with invariant gamma delta antigen receptors. Science 252:1430-32
40. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, et al. 2001. Regulation of cutaneous malignancy by gamma delta T cells. Science 294:605-9
41. Lanier LL. 1998. NK cell receptors. Annu. Rev. Immunol. 16:359-93
42. Bakker ABH, Wu J, Phillips JH, Lanier LL. 2000. NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. Hum. Immunol. 61:18-27
43. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, et al. 2001. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19:197-223
44. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, et al. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727-29
45. Wu J, Song Y, Bakker ABH, Bauer S, Spies T, et al. 1999. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285:730-32
46. Cerwenka A, Bakker ABH, McClanahan T, Wagner J, Wu J, et al. 2000. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12:721-27
47. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. 2000. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat. Immunol. 1:119-26
48. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. 1996. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA 93:12445-50
49. Groh V, Steinle A, Bauer S, Spies T. 1998. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 279:1737-40
50. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. 1999. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA 96:6879-84
51. Cosman D, Müllberg J, Sutherland CL, Chin W, Armitage R, et al. 2001. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:123-33
52. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. 2001. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165-71
53. Cerwenka A, Baron JL, Lanier LL. 2001. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA 98:11521-26
54. Groh V, Rhinehart R, Randolph-Habecker J, Topps MS, Riddell SR, Spies T. 2001. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2:255-60
55. Sutherland C, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D. 2002. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J. Immunol. 168:671-79
56. Harada Y, Tanabe E, Watanabe R, Weiss BD, Matsumota A, et al. 2001. Novel role of phosphatidylinositol 3-kinase in CD28-mediated costimulation. J. Biol. Chem. 276:900-8
57. Lu Y, Cuevas B, Gibson S, Khan H, La-Pushin R, et al. 1998. Phosphatidylinositol 3-kinase is required for CD28 but not CD3 regulation of the TEC family tyrosine kinase EMT/ITK/TSK: functional and physical interaction of EMT with phosphatidylinositol 3-kinase. J. Immunol. 161:5404-12
58. Prasad KVS, Cai YC, Raab M, Duckworth B, Cantley L, et al. 1994. T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc. Natl. Acad. Sci. USA 91:2834-38
59. Pages F, Ragueneau M, Rottapel R, Truneh A, Nunes J, et al. 1994. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 369:327-29
60. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. 2002. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17:19-29
61. Esteban F, Concha A, Delgado M, Perez-Ayala M, Ruiz-Cabello F, et al. 1990. Lack of MHC class I antigens and tumour aggressiveness of the squamous cell carcinoma of the larynx. Br. J. Cancer 62:1047-51
62. Esteban F, Concha A, Huelin C, Perez-Ayala, Pedrinaci S, et al. 1989. Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. Int. J. Cancer 43:436-42
63. Esteban F, Redondo M, Delgado M, Garrido F, Ruiz-Cabello F. 1996. MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up. Br J. Cancer 74:1801-4
64. Ferrone S, Marincola FM. 1995. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16:487-94
65. Natali PG, Bigotti A, Nicotra MR, Viora M, Manfredi D, et al. 1984. Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res. 44:4679-87
66. Natali P, Bigotti A, Cavaliere R, Liao SK, Taniguchi M, et al. 1985. Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma. Cancer Res. 45:2883-89
67. Natali PG, Cavaliere R, Bigotti A, Nicotra MR, Russo C, et al. 1983. Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J. Immunol. 130:1462-66
68. Natali PG, Nicotra MR, Bigotti A, Venturo I, Marcenaro L, et al. 1989. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc. Natl. Acad. Sci. USA 86:6719-23
69. Perez M, Cabrero T, Lopez Nevot MA, Gomez M, Peran F, et al. 1986. Heterogeneity of the expression of class I and II HLA antigens in human breast carcinoma. J. Immunogenet. 13:247-53
70. Whitwell HL, Hughes HP, Moore M, Ahmed A. 1984. Expression of major histocompatibility antigens and leucocyte infiltration in benign and malignant human breast disease. Br. J. Cancer 49:161-72
71. Zuk JA, Walker RA. 1987. Immunohistochemical analysis of HLA antigens and mononuclear infiltrates of benign and malignant breast. J. Pathol. 152:275-85
72. Ruiz-Cabello F, Lopez Nevot MA, Gutierrez J, Oliva MR, Romero C, et al. 1989. Phenotypic expression of histocompatibility antigens in human primary tumours and metastases. Clin. Exp. Metastasis 7:213-26
73. Ruiz-Cabello F, Perez-Ayala M, Gomez O, Redondo M, Concha A, et al. 1991. Molecular analysis of MHC-class-I alterations in human tumor cell lines. Int. J. Cancer Suppl. 6:123-30
74. Cabrera T, Fernandez MA, Sierra A, Garrido A, Herruzo A, et al. 1996. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum. Immunol. 50:127-34
75. Cabrera T, Collado A, Fernandez MA, Ferron A, Sancho J, et al. 1998. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens 52:114-23
76. van den Ingh HF, Ruiter DJ, Griffioen G, van Muijen GN, Ferrone S. 1987. HLA antigens in colorectal tumours - low expression of HLA class I antigens in mucinous colorectal carcinomas. Br. J. Cancer 55:125-30
77. van Driel WJ, Tjiong MY, Hilders CG, Trimbos BJ, Fleuren GJ. 1996. Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma. Gynecol. Oncol. 62:33-41
78. Marincola F, Jaffee E, Hicklin D, Ferrone S. 2000. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74:181-273
79. D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. 1991. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J. Clin. Invest. 87:284-92
80. Wang Z, Cao Y, Albino AP, Zeff RA, Houghton A, Ferrone S, et al. 1993. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J. Clin. Invest. 91:684-92
81. Bicknell DC, Rowan A, Bodmer WF. 1994. Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc. Natl. Acad. Sci. USA 91:4751-56
82. Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jiménez M, et al. 1998. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52:520-29
83. Blanchet O, Bourge J, Zinszner H, Israel A, Kourilsky P. 1992. Altered binding of regulatory factors to HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression. Proc. Natl. Acad. Sci. USA 89:3488-92
84. Doyle A, Martin WJ, Funa K, Gazdar A, Carney D, et al. 1985. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J. Exp. Med. 161:1135-51
85. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. 1996. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst. 88:100-8
86. Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, et al. 1995. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur. J. Immunol. 25:1374-84
87. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, et al. 1995. Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst. 87:280-85
88. Alpan RS, Zhang M, Pardee AB. 1996. Cell cycle-dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line. Cancer Res. 56:4358-61
89. Seliger B, Hohne A, Knuth A, Bernhard H, Ehring B, et al. 1996. Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin. Cancer Res. 2:1427-33
90. Hilders CG, Houbiers JG, Krul EJ, Fleuren GJ. 1995. The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma. Am. J. Clin. Pathol. 101:5-12
91. Koopman L, Corver W, van der Slik A, Giphart M, Fleuren G. 2000. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J. Exp. Med. 191:961-76
92. Clarke B, Chetty R. 2002. Postmodern cancer: the role of human immunodeficiency virus in uterine cervical cancer. Mol. Pathol. 55:19-24
93. Moretta A, Biassoni R, Bottino C, Pende D, Vitale M, et al. 1997. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol. Rev. 155:105-17
94. Lanier LL, Phillips JH. 1996. Inhibitory MHC class I receptors on NK cells and T cells. Immunol. Today 17:86-91
95. Hui K, Grosveld F, Festenstein H. 1984. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311:750-52
96. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, et al. 1985. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315:301-5
97. Haywood GR, McKhann CF. 1971. Antigenic specificities on murine sarcoma cells. Reciprocal relationship between normal transplantation antigens (H-2) and tumor-specific immunogenicity. J. Exp. Med. 133:1171-87
98. Ljunggren HG, Karre K. 1985. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J. Exp. Med. 162:1745-59
99. Karre K, Ljunggren HG, Piontek G, Kiessling R. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675-78
100. Urban JL, Burton RC, Holland JM, Kripke ML, Schreiber H. 1982. Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J. Exp. Med. 155:557-73
101. Uyttenhove C, Maryanski J, Boon T. 1983. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157:1040-52
102. Wortzel RD, Philipps C, Schreiber H. 1983. Multiple tumour-specific antigens expressed on a single tumour cell. Nature 304:165-67
103. Urban JL, Kripke ML, Schreiber H. 1986. Stepwise immunologic selection of antigenic variants during tumor growth. J. Immunol. 137:3036-41
104. Ward PL, Koeppen H, Hurteau T, Schreiber H. 1989. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J. Exp. Med. 170:217-32
105. Ward PL, Koeppen HK, Hurteau T, Rowley DA, Schreiber H. 1990. Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. Cancer Res. 50:3851-58
106. Lethe B, van den Eynde B, van Pel A, Corradin G, Boon T. 1992. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur. J. Immunol. 22:2283-88
107. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, et al. 2002. Adoptively transferred antigen-specific CD8+ T cell clones persist in vivo, migrate to tumor sites and mediate antigen-specific immune response in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 99:16168-73
108. Jager E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, et al. 1997. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer 71:142-47
109. Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, et al. 2001. Short-term kinetics of tumor antigen expression in response to vaccination. J. Immunol. 167:1809-20
110. de Vries T, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GN. 1997. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 57:3223-29
111. Cormier JN, Abati A, Fetsch P, Hijazi YM, Rosenberg SA, et al. 1998. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J. Immunother. 21:27-31
112. Cormier J, Panelli MC, Hackett JA, Bettinotti MP, Mixon A, et al. 1999. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int. J. Cancer 80:781-90
113. Riker A, Cormier J, Panelli M, Kammula U, Wang E, et al. 1999. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126:112-20
114. Scheibenbogen C, Weyers I, Ruiter D, Willhauck M, Bittinger A, Keilholz U. 1996. Expression of gp100 in melanoma metastases resected before or after treatment with IFN alpha and IL-2. J. Immunother. Emphas. Tumor Immunol. 19:375-80
115. Schmid P, Itin P, Rufli T. 1995. In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma. Carcinogenesis 16:1499-503
116. Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, et al. 1997. In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res. 7:313-21
117. Van Belle P, Rodeck U, Nuamah I, Halpern A, Elder D. 1996. Melanoma-associated expression of transforming growth factor-beta isoforms. Am. J. Pathol. 148:1887-94
118. Wojtowicz-Praga S, Vermia UN, Wakefield L, Esteban JM, Hartmann D, et al. 1996. Modulation of b16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. Immunotherapy 19:169-75
119. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, et al. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363-66
120. Gratas C, Tohma Y, VanMeir EG, Klein M, Tenan M, et al. 1997. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 7:863-69
121. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, et al. 1998. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160:5669-75
122. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, et al. 1997. Human lung carcinomas express Fas ligand. Cancer Res. 57:1007-12
123. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075-82
124. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H. 1997. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA 94:6420-25
125. Chappell DB, Zaks TZ, Rosenberg SA, Restifo NP. 1999. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res. 59:59-62
126. Seino K, Kayagaki N, Okumura K, Yagita H. 1997. Antitumor effect of locally produced CD95 ligand. Nat. Med. 3:165-70
127. Arai H, Gordon D, Nabel EG, Nabel GJ. 1997. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. USA 94:13862-67
128. Bogen B, Munthe L, Sollien A, Hofgaard P, Omholt H, et al. 1995. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur. J. Immunol. 25:3079-86
129. Bogen B. 1996. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J. Immunol. 26:2671-79
130. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, et al. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95:1178-83
131. Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, et al. 2001. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98:1070-77
132. Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, et al. 1997. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186:229-38
133. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKallfaienza K, et al. 1997. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645-53
134. Doan T, Herd KA, Lambert PF, Fernando GJP, Street MD, Tindle RW. 2000. Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization. Cancer Res. 60:2810-15
135. den Boer AT, Diehl L, van Mierlo GJD, van der Voort EIH, Fransen MF, et al. 2001. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J. Immunol. 167:2522-28
136. Shrikant P, Khoruts A, Mescher MF. 1999. CTLA4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 11:483-93
137. Schell TD, Knowles BB, Tevethia SS. 2000. Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. Cancer Res. 60:3002-12
138. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, et al. 2001. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411:1058-64
139. Huang AY, Golumek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961-65
140. Robinson BWS, Scott BM, Lake RA, Stumble PA, Nelson DJ, et al. 2001. Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis - implications for tumor tolerance. Clin. Cancer Res. 7:S811-17
141. Nguyen LT, Elford AR, Murakami K, Garza KM, Schoenberger SP, et al. 2002. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med. 195:423-35
142. Morck A, Santarsiero L, Armstrong T, Chen Y, Huang L, et al. 2002. Functional genomics identifies mesothelin as an immunodominant pancreatic cancer antigen. Submitted
143. Drake C, Higgins A, Mihalyo M, Kennedy E, Adler A. 2003. Prostate tumorogenesis induces tolerance in prostate specific T cells. Submitted
144. Sakaguchi S, Sakaguchi N, Shimizu J, Yamagaki S, Sakihara T, et al. 2001. Immunologic tolerance maintained by CD35+ CD4+ regulatory cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182:18-32
145. Shevach E. 2002. CD4+ CD25+ supppressor T cells: more questions than answers. Nat. Rev. Immunol. 2:389-400
146. Maloy K, Powrie F. 2001. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2:816-22
147. Sutmuller RPM, van Dulvenvoorde LM, van Elsas A, Schumacher TNM, Wildenberg ME, et al. 2001. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocte responses. J. Exp. Med. 194:823-32
148. van Elsas A, Sutmuller RPM, Hurwitz AA, Ziskin J, Villasenor J, et al. 2001. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194:481-89
149. Ercolini A, Armstrong T, Reilly T, Jaffee E. 2002. Inhibition of T regulatory cells by cytoxan releases high avidity T cells specific for immunodominant epitopes of HER-2/neu. Submitted
150. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, et al. 2001. Cyclophosphamide, doxorubin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61(9):3689-97
151. Catlett-Galcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, et al. 1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10:105-15
152. Wang T, Niu G, Burdelya L, Shain K, Zhang S, et al. 2002. Regulation of the innate and adaptive immune responses by Stat3 signaling in tumor cells. Submitted
153. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, et al. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2:1096-103
154. Niu GL, Wright KL, Huang M, Song LX, Haura E, et al. 2002. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21:2000-8
155. Kulkami A, Karlsson S. 1993. Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am. J. Pathol. 143:3-9
156. Leveen P, Larsson J, Ehinger M, Cilio CM, Sundler M, et al. 2002. Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood 100:560-68
157. Chen W, Wahl S. 2002. TGF-beta: receptors, signaling pathways and autoimmunity. Curr. Dir. Autoimmun. 5:62-91
158. Adler AJ, Marsh DW, Yochum GS, Guzzo JL, Nigam A, et al. 1998. CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J. Exp. Med. 187:1555-64
159. Steinman R, Rurley S, Mellman I, Inaba K. 2000. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 191:411-16
160. Legge K, Gregg RK, Maldonado-Lopez R, Li LQ, Caprio JC, et al. 2002. On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity. J. Exp. Med. 196:217-27
161. Steinman R, Nussenzweig M. 2002. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99:351-58
162. Pardoll D. 2002. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2:227-38
163. Dong H, Zhu G, Tamada K, Chen L. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5:1365-1369
164. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chervova T, et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 197:1027-34
165. Tseng S-Y, Gorski K, Huang X, Slansky J, Pai S, et al. 2001. B7-DC, a new dendritic cell molecule with unique costimulatory properties fort cells. J. Exp. Med. 193:839-46
166. Latchman Y, Wood CR, Chemova T, Chaudhary D, Borde M, et al. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2:261-68
167. Kim JJ, Bagarazzi ML, Trivedi N, Hu Y, Kazahaya K, et al. 1997. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat. Biotechnol. 15:631-36
168. Agadjanyan MG, Kim JJ, Trivedi N, Wilson DM, Monzavi-Karbassi B, et al. 1999. CD86(B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo. J. Immunol. 162:3417-27
169. Chambers CA, Kuhns MS, Egen JG, Allison JP. 2001. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19:565-94
170. van Elsas A, Hurwitz A, Allison J. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4(CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190:355-66
171. Hurwitz A, Foster BA, Kwon ED, Truong T, Choi EM, et al. 2000. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA4 blockade. Cancer Res. 60:2444-48
172. Hernandez J, Ko A, Sherman LA. 2001. CTLA4 blockade enhances the CTL responses to the p53 self-tumor antigen. J. Immunol. 166:3908-14
173. Nanda N, Sercarz E. 1995. Induction of anti-self-immunity to cure cancer. Cell 82:13-17
174. Cox A, Skipper J, Chen Y, Henderson R, Darrow T, et al. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-19
175. Slingluff CJ, Hunt D, Engelhard V. 1994. Direct analysis of tumor-associated peptide antigens. Curr. Opin. Immunol. 6:733-40
176. Gervois N, Guilloux Y, Diez E, Jotereau F. 1996. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J. Exp. Med. 183:2403-7
177. Slansky J, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, et al. 2000. Enhance antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13:529-38
178. Parkhurst M, Salgaller ML, Southwood S, Robbins P, Sette A, et al. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157:2539-48
179. Dyall R, Bowne WB, Weber LW, LeMaoult J, Szabo P, et al. 1998. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188:1553-61
180. Tangri S, Ishioka GY, Huang XQ, Sidney J, Southwood S, et al. 2001. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J. Exp. Med. 194:833-46
181. Bullock TN, Mullins DW, Colella TA, Engelhard VH. 2001. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice. J. Immunol. 167:5824-31
182. Hoffmann TK, Loftus DJ, Nakano K, Maeurer MJ, Chikamatsu K, et al. 2002. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope. J. Immunol. 168:1338-47
183. Colella TA, Bullock TNJ, Russell LB, Mullins DW, Overwijk WW, et al. 2000. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J. Exp. Med. 191:1221-32
184. Morgan D, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160:643-51
185. Cordaro TA, de Visser KE, Tirion FH, Schumacher TN, Kruisbeek AM. 2002. Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection? J. Immunol. 168:651-60
186. Lally KM, Mocillin S, Ohnmacht GA, Nielsen MB, Bettinotti M, et al. 2001. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int. J. Cancer 93:841-47
187. Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, et al. 2002. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J. Immunol. 168:5900-6
188. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, et al. 2002. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20:2624-32
189. Ohlen C, Kalos M, Hong DJ, Shur AC, Greenberg PD. 2001. Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen. J. Immunol. 166:2863-70